331 related articles for article (PubMed ID: 28808873)
41. Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy.
Mohammad AM; Abdel HA; Abdel W; Ahmed AM; Wael T; Eiman G
Indian J Cancer; 2006; 43(4):163-8. PubMed ID: 17192687
[TBL] [Abstract][Full Text] [Related]
42. Low protein expression of MET in ER-positive and HER2-positive breast cancer.
Zagouri F; Brandstetter A; Moussiolis D; Chrysikos D; Dimitrakakis C; Tsigginou A; Marinopoulos S; Zografos GC; Sergentanis TN; Dimopoulos MA; Filipits M
Anticancer Res; 2014 Mar; 34(3):1227-31. PubMed ID: 24596364
[TBL] [Abstract][Full Text] [Related]
43. Implications of New Lumpectomy Margin Guidelines for Breast-Conserving Surgery: Changes in Reexcision Rates and Predicted Rates of Residual Tumor.
Merrill AL; Coopey SB; Tang R; McEvoy MP; Specht MC; Hughes KS; Gadd MA; Smith BL
Ann Surg Oncol; 2016 Mar; 23(3):729-34. PubMed ID: 26467458
[TBL] [Abstract][Full Text] [Related]
44. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
45. Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact.
Dhakal HP; Naume B; Synnestvedt M; Borgen E; Kaaresen R; Schlichting E; Wiedswang G; Bassarova A; Holm R; Giercksky KE; Nesland JM
Histol Histopathol; 2012 Oct; 27(10):1315-25. PubMed ID: 22936450
[TBL] [Abstract][Full Text] [Related]
46. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
[TBL] [Abstract][Full Text] [Related]
47. Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer.
Lukosiute-Urboniene A; Jasukaitiene A; Silkuniene G; Barauskas V; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2019 Jan; 25(2):205-219. PubMed ID: 30670910
[TBL] [Abstract][Full Text] [Related]
48. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
49. Breast Cancer in Men: a Report from the Department of Radiation Oncology in Kermanshah Province, Iran.
Amirifard N; Sadeghi E
Asian Pac J Cancer Prev; 2016; 17(5):2593-6. PubMed ID: 27268636
[TBL] [Abstract][Full Text] [Related]
50. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
51. PSMB4 overexpression enhances the cell growth and viability of breast cancer cells leading to a poor prognosis.
Wang H; He Z; Xia L; Zhang W; Xu L; Yue X; Ru X; Xu Y
Oncol Rep; 2018 Oct; 40(4):2343-2352. PubMed ID: 30066880
[TBL] [Abstract][Full Text] [Related]
52. Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment.
Stefanovic S; Diel I; Sinn P; Englert S; Hennigs A; Mayer C; Schott S; Wallwiener M; Blumenstein M; Golatta M; Heil J; Rom J; Sohn C; Schneeweiss A; Schuetz F; Domschke C
Ann Surg Oncol; 2016 Mar; 23(3):757-66. PubMed ID: 26467455
[TBL] [Abstract][Full Text] [Related]
53. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer.
Magkou C; Giannopoulou I; Theohari I; Fytou A; Rafailidis P; Nomikos A; Papadimitriou C; Nakopoulou L
Histopathology; 2012 Jun; 60(7):1125-32. PubMed ID: 22320867
[TBL] [Abstract][Full Text] [Related]
55. Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma.
El-Gendi SM; Mostafa MF
Pathol Oncol Res; 2016 Jul; 22(3):461-70. PubMed ID: 26597806
[TBL] [Abstract][Full Text] [Related]
56. Human antigen R is positively associated with malignant aggressiveness via upregulation of cell proliferation, migration, and vascular endothelial growth factors and cyclooxygenase-2 in prostate cancer.
Mitsunari K; Miyata Y; Asai A; Matsuo T; Shida Y; Hakariya T; Sakai H
Transl Res; 2016 Sep; 175():116-28. PubMed ID: 27140699
[TBL] [Abstract][Full Text] [Related]
57. The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast.
Barısık NO; Keser SH; Gul AE; Sensu S; Kandemir NO; Kucuk HF; Gumus M; Karadayı N
Med Oncol; 2011 Sep; 28(3):703-8. PubMed ID: 20354817
[TBL] [Abstract][Full Text] [Related]
58. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
[TBL] [Abstract][Full Text] [Related]
59. Impact of Consensus Guidelines by the Society of Surgical Oncology and the American Society for Radiation Oncology on Margins for Breast-Conserving Surgery in Stages 1 and 2 Invasive Breast Cancer.
Chung A; Gangi A; Amersi F; Bose S; Zhang X; Giuliano A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S422-7. PubMed ID: 26310280
[TBL] [Abstract][Full Text] [Related]
60. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
